The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

The combination of Keytruda (pembrolizumab) and Welireg (belzutifan) improved disease-free survival compared with Keytruda ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Kidney cancer is not exclusively a disease of older patients. For many young adults, the diagnosis comes as a shock, often appearing without warning in those who otherwise feel healthy.

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

Mehra added that research in head and neck cancer is entering an exciting phase, with growing interest in bispecific antibodies targeting EGFR. With newer dual-targeting agents, including Rybrevant, ...

Director of Head and Neck Oncology in the Division of Hematology/Oncology and associate director for Clinical Research at the University of Maryland School of Medicine.

Developing assertiveness is portrayed as a protective shift from people-pleasing and emotional suppression toward clearer ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...